The Camp Lejeune Track 1 Trial Bargain: 25 Plaintiffs, Five Diseases, Every Other Claim Waived

A Camp Lejeune Track 1 trial is a single-plaintiff bench trial in the Eastern District of North Carolina, drawn from a pool of 25 claimants who were selected in July 2024 on the condition that they abandon every injury claim outside five designated diseases. On 22 September 2026 Roll Call reported that Lori Freshwater, a Rhode Island writer and health researcher, had accepted a $400,000 Justice Department settlement for her mother's death while her own claims and those over her two baby brothers stay on the docket — a settlement taken, as she put it, because "there will never be true justice for our losses." That is the trade-off the Camp Lejeune Track 1 trial structure has produced: a fixed sum now, or a trial in November before a judge, with no jury, in a case stripped down to one disease.

The first two trials are set. Judge Terrence W. Boyle has calendared Mousser for 9 November 2026 and Fancher for 16 November 2026 in Elizabeth City, North Carolina, with each expected to take two or three days. Behind them sit roughly 3,800 filed lawsuits and more than 409,000 administrative claims lodged with the Department of the Navy. Behind those sits a court-set target date of 30 October 2026 for the parties to produce a framework resolving all of it.

What is a Camp Lejeune Track 1 trial?

A Camp Lejeune Track 1 trial is the first of three staged trial groups the Eastern District of North Carolina created to work through claims under the Camp Lejeune Justice Act, Section 804 of the Honoring our PACT Act. Rather than certify a class or coordinate through the Judicial Panel on Multidistrict Litigation (JPML), the four judges of the district divided the inventory into tracks by disease, ordered discovery and expert work to proceed track by track, and selected a small number of representative plaintiffs whose cases would actually be tried.

The mechanics resemble a Bellwether Trial in a Mass Tort, and practitioners use the words interchangeably, but the analogy is imperfect in a way that matters later in this article. There is no Multidistrict Litigation (MDL) here, no transferee judge holding cases for pretrial purposes, and no suggestion of remand at the end. The Camp Lejeune cases were filed in a single district because the statute requires it, and they will be tried in that district by the judges who managed them.

The Track 1 pretrial schedule ran in three phases: a Water Contamination Phase addressing the modeled exposure evidence common to every claimant, a General Causation Phase addressing whether the contaminants can cause the listed diseases at all, and a Residual Expert Phase covering Specific Causation and damages. Fact discovery as to the Track 1 plaintiffs closed in August 2024, with expert disclosures following. According to Miller & Zois's running litigation update, expert discovery across water contamination, general causation, individual causation, damages and offsets was substantially complete by 24 August 2026, with Daubert Challenge and summary judgment briefing largely finished.

Which illnesses are in Camp Lejeune Track 1, and how were the 25 trial plaintiffs picked?

Track 1 comprises five illnesses: kidney cancer, bladder cancer, leukemia, non-Hodgkin lymphoma and Parkinson's disease. The scope was contested. The government pressed for a three-disease Track 1 — kidney cancer, leukemia and Parkinson's disease — and the Plaintiffs' Leadership Group pressed for five. The plaintiffs prevailed on scope, which is why bladder cancer and non-Hodgkin lymphoma are in the first wave rather than the second.

Selection followed a protocol the parties proposed jointly and the court adopted. From a larger Track 1 discovery pool, the Plaintiffs' Leadership Group proposed three plaintiffs for each of the five illnesses and the government proposed two, producing five Trial Plaintiffs per disease and 25 in total. The order confirming the list was entered on 9 July 2024 and signed by all four judges of the district — Chief Judge Richard E. Myers II, Judge Terrence W. Boyle, Judge Louise W. Flanagan and Judge James C. Dever III — an unusual formality that reflects how the district has run this litigation as a single managed docket rather than four separate ones.

Track 1 element	Position as of 22 September 2026
Illnesses in Track 1	Kidney cancer, bladder cancer, leukemia, non-Hodgkin lymphoma, Parkinson's disease
Trial Plaintiffs	25 — five per illness
Proposing party	Three per illness from the Plaintiffs' Leadership Group, two per illness from the United States
Selection order	Entered 9 July 2024, signed by all four district judges
Pretrial phases	Water Contamination, General Causation, Residual Expert
Expert discovery	Substantially complete as of late August 2026
First trials set	Mousser, 9 November 2026 (kidney cancer); Fancher, 16 November 2026
Trial location	Elizabeth City, North Carolina
Mode of trial	Bench trial; no jury
Expected length	Two to three days each
Leukemia and non-Hodgkin lymphoma group	Assigned to Judge Dever

Do Camp Lejeune Track 1 trial plaintiffs have to give up their other claims?

Yes. Each Track 1 Trial Plaintiff waived the right to allege that any illness or injury other than a Track 1 illness — or a condition flowing from a Track 1 illness or its treatment — was caused by the water at Camp Lejeune. The waiver is not a background understanding; it is executed on the docket. Selected plaintiffs were required to amend their Short Form Complaints within ten days to strike the waived conditions, so that the pleading going into trial matches the single disease being tried.

This is the least-reported feature of the Camp Lejeune Track 1 trial structure and the one with the sharpest consequences for individual claimants. Camp Lejeune exposure claims are frequently multi-injury. A Marine stationed at the base between 1953 and 1987 who developed both bladder cancer and a second qualifying condition, or who has a Track 1 cancer alongside a non-Track 1 diagnosis such as multiple myeloma or a hepatic condition, does not get to try the whole of their case. To become a Trial Plaintiff, they hand back the rest.

The court's logic is defensible and familiar from Mass Tort practice. A trial group is useful only if the cases in it are comparable. Allowing a Trial Plaintiff to present a multi-injury damages picture would make the resulting award impossible to read as a signal about the disease being tested, which is the entire point of running the exercise. A single-disease rule keeps the November results legible.

The cost is borne by 25 people, and it is not symmetrical. The government gives up nothing equivalent. A Trial Plaintiff who loses on general causation for kidney cancer has also surrendered the claims they might otherwise have pressed. A Trial Plaintiff who wins has established a value for one disease in one case. Claimants' counsel weighing whether to put a client forward for a trial slot are making a decision that is, for that client, closer to an election of remedies than to a procedural convenience.

When is the first Camp Lejeune trial, and what will it decide?

The first Camp Lejeune trial begins on 9 November 2026 in Elizabeth City, North Carolina, in Mousser, a kidney cancer case before Judge Boyle, followed by Fancher on 16 November 2026. Public Radio East reported on 16 September 2026 that both are set as non-jury trials and that each is expected to run two to three days — short, because the judge hearing them has lived with the litigation's common issues for years and does not need the scientific record built from scratch.

What the November trials will decide is narrower than the coverage suggests. They will decide whether these plaintiffs, on this record, have shown that exposure to the contaminated water at Camp Lejeune caused their kidney cancer, and if so what damages the court awards after statutory offsets. In Mousser that means weighing competing epidemiology: a federal cancer-incidence study that found no statistically significant overall increase against Agency for Toxic Substances and Disease Registry research associating Camp Lejeune contaminants with kidney cancer.

What they will not decide is the value of anyone else's claim. Separately, the Track 1 leukemia and non-Hodgkin lymphoma cases are headed to Judge Dever, on a joint proposal that positioned those groups behind the kidney cancer cases. Four Track 1 trials in total are moving toward the scheduling stage.

Why is there no jury trial in Camp Lejeune cases?

There is no jury because in February 2024 the four judges of the Eastern District of North Carolina held that the Camp Lejeune Justice Act does not confer one. The reasoning was sovereign immunity: a suit against the United States proceeds only on the terms Congress sets, and Congress is presumed not to have authorized jury trials against the government unless it says so clearly. The judges found that the Act did not clearly and unequivocally depart from that default. On 13 May 2024 the court unanimously declined to certify the question for interlocutory appeal, which is why the point has never reached the Fourth Circuit.

The statutory text is the awkward part. Section 804(d) contains a sentence providing that nothing in the subsection shall impair the right of any party to a trial by jury. Plaintiffs read that as preserving a jury right; the court read it as preserving whatever jury right otherwise existed, which — against the United States, absent an express waiver — is none. Roll Call reported the ruling on 6 February 2024 and Bloomberg Law covered the same decision; the practical effect has governed every day of the litigation since.

The consequence for the November trials is structural, not cosmetic. Bench trials in a toxic exposure case change the evidentiary center of gravity. There is no jury to be moved by a plaintiff's testimony about a mother's death or a Marine's decades of illness, and no jury to be confused by competing epidemiology. There is a judge who has already read the Daubert briefing, already knows the water modeling, and will write findings of fact. It compresses the trial to two or three days. It also removes the mechanism that generates outlier awards in state-court toxic tort practice, which is precisely why the government has never sought to disturb the ruling and the plaintiffs' bar has gone to Congress to try to reverse it.

The four constraints Section 804 puts on every Camp Lejeune case

The Camp Lejeune Track 1 trial design is not a case management preference. It is the shape a litigation takes when Congress writes four constraints into the cause of action.

Exclusive jurisdiction and venue. Section 804 gives the United States District Court for the Eastern District of North Carolina exclusive jurisdiction over CLJA actions and makes it the exclusive venue. Every one of the roughly 3,800 filed suits is in one district before four judges. There is no transfer valve, no parallel state-court track and no JPML mechanism to spread the load, because there is nothing to coordinate — the cases were never anywhere else.

No punitive damages. The statute forecloses Punitive Damages outright. In an ordinary Mass Tort against a corporate defendant, the prospect of a punitive award is what converts a modest compensatory verdict into a settlement-moving event. Here that lever does not exist, and the ceiling on any single trial result is compensatory.

Mandatory offsets. A court award must be reduced by the amount of any related disability award, payment or benefit already provided in connection with the same exposure — Department of Veterans Affairs disability compensation, and payments under Medicare and Medicaid-type programs. The Department of Veterans Affairs is explicit that filing under the Act does not affect eligibility for VA disability or health care, and that a court award does not reduce ongoing VA payments; the offset runs the other way, against the litigation recovery. For a long-service veteran with a substantial disability rating, the offset can consume a large share of a compensatory award before any Medical Lien is addressed.

A limitations period that has already closed. A claim could not be commenced after the later of two years from enactment or 180 days after the Navy denied the administrative claim. The filing window for new administrative claims shut in August 2024. The population is therefore fixed. Unlike a growing Mass Tort where intake continues and Claim Value is re-estimated as the docket expands, the Camp Lejeune inventory is a closed set of more than 409,000 administrative claims and roughly 3,800 suits.

Those four constraints explain almost everything that follows: why the trials are short, why they are before a judge, why the government has been willing to price claims administratively rather than litigate them, and why both sides are under pressure to reach a Global Settlement rather than try their way through a closed but enormous inventory.

The causation fight running underneath the trial schedule

Section 804(b) sets a relaxed causation standard: a claimant must produce evidence showing that the relationship between exposure and harm is sufficient to conclude that it is at least as likely as not that the exposure caused the harm. That language was written to be easier to satisfy than ordinary tort causation, and it is the principal reason Congress's intervention mattered at all.

What the standard means in practice has been litigated hard. On 1 April 2026 the Department of Justice moved for an early ruling that the Act still requires but-for causation, which would restore a stricter test than the statutory phrase suggests. The Carlson Law Firm reports that on 5 June 2026 the court issued three orders — docket entries 884, 885 and 886 — addressing the causation standard, the timing of expert disclosures and the statutory offsets. The district's rulings to date have read the standard more demandingly than the plaintiffs sought, declining to adopt the loosest available construction.

The distinction between General Causation and Specific Causation carries unusual weight here because of the trial structure. General causation is common to everyone with a given disease; specific causation is individual. A Track 1 trial tests both at once in a single plaintiff, and a loss can come from either. A judgment for the government in Mousser would not tell claimants' counsel whether kidney cancer claims failed as a class of claims or whether one plaintiff's exposure history was too thin — unless the findings of fact say so. In a bench trial they will say so, which is one of the few respects in which the absence of a jury favors the claimant side. Written findings are appealable in a way a general verdict is not.

Should a claimant accept a Camp Lejeune settlement offer or wait for trial?

There is no general answer, and the Roll Call story is valuable precisely because it shows the calculation being made rather than described. Freshwater took $400,000 for her mother's death while her remaining claims stay pending, and said she struggled with the decision at a moment when the litigation appears close to a resolution that could require the government to pay out billions. Analysis rather than advice: the variables that actually move the decision are the offset exposure, the disease band, the claimant's health and age, and whether the claim is one the Elective Option will price at all.

The Elective Option is a non-negotiated administrative program under which the government prices qualifying claims from a published grid keyed to diagnosis and length of exposure. It resolves a claim quickly and without proof of specific causation at trial. It is also narrow: it covers a defined list of conditions, requires documentary proof of presence at the base, and — as claimants argued in an emergency motion filed on 15 September 2026 over offers due to lapse on 27 September — is administered in a way claimants cannot readily audit.

Weighing an administrative offer against the litigation track means pricing five things:

• The offset. A veteran receiving substantial VA disability compensation for a Camp Lejeune condition faces a statutory reduction against any court award. That reduction does not apply in the same way to an administrative settlement figure, which is set as a gross number.
• The absence of punitive damages. Nothing in the litigation track pays more than compensatory damages, so the upside over an administrative offer is bounded by the compensatory delta, not by an order of magnitude.
• Time. The first trials are in November 2026, nearly four and a half years after enactment. Appeals from a bench judgment would add years. Many claimants in this population are elderly or terminally ill.
• Liens and fees. Any recovery is net of Medical Lien resolution and a Contingency Fee. The figure a claimant keeps from a $400,000 settlement is not $400,000.
• Waiver scope. An Elective Option acceptance resolves the claim it prices. A Track 1 trial slot, as above, extinguishes claims for every non-Track 1 condition.

The population splits roughly into three groups: claimants with a listed diagnosis, clean documentation and low offset exposure, for whom the administrative route is usually the rational choice; claimants with severe injury, weak offsets and strong exposure proof, for whom waiting has real option value; and the large middle, for whom the answer depends on what the 30 October framework looks like.

What is the 30 October 2026 Camp Lejeune settlement deadline?

It is the date by which the court has directed the parties, working with settlement masters, to produce a framework for globally resolving the Camp Lejeune inventory. It is not a statutory deadline and it does not expire anyone's claim. It is a case management target with a credible threat behind it: the court has signaled that if the parties cannot produce a framework, it will consider consequences including changes to plaintiffs' leadership and sanctions directed at government counsel.

Practitioners should read 30 October and 9 November together. The framework target sits three weeks before the first trial, which is deliberate. A global resolution negotiated before any judgment is priced off uncertainty; a resolution negotiated after two kidney cancer judgments is priced off data. Both sides know which they prefer, and neither knows which way the data will run. That is the classic configuration in which mass settlements actually get done.

A framework, if one emerges, would most likely look like the Settlement Matrix structures familiar from other mass resolutions: tiers by diagnosis, multipliers for exposure duration and age at diagnosis, a Special Master or Claims Administrator to run allocation, a mechanism for handling the offsets the statute requires, and possibly a Qualified Settlement Fund (QSF) to hold and distribute proceeds. None of that is public, and no dollar figure has been announced. Competing coverage that projects settlement values per disease is projecting, not reporting.

How much has the government paid in Camp Lejeune settlements so far?

Published totals for the Elective Option have risen steadily through 2026 and, importantly, conflict between sources — a reminder that the government has not maintained a single authoritative public running total. The two best-corroborated snapshots are these.

Date of report	Settlement offers extended	Payments made
15 June 2026	Over $907 million	Over $723 million
17 July 2026	Over $968 million	Over $801 million

Two features of that table matter more than the headline numbers. First, the gap between offers and payments — roughly $167 million in July — is the float of accepted-but-unpaid and offered-but-undecided claims, and it is where the 27 September expiry dispute is being fought. Second, the trajectory is roughly $60 million in new offers and $78 million in new payments over about a month. Against more than 409,000 pending administrative claims, that run rate does not resolve this litigation in any horizon a claimant population of this age can wait out. The Elective Option is a relief valve, not a resolution.

For context on scale: roughly 3,800 suits are on file in the Eastern District of North Carolina, against more than 409,000 administrative claims with the Navy. Reported lawsuit counts in September 2026 range between 3,744 and 3,784 depending on the reporting date, which is ordinary docket drift rather than disagreement. The ratio — about one filed suit for every 108 administrative claims — is the single most important number in the litigation, because it defines what happens if the administrative route fails.

Will Congress change the Camp Lejeune Justice Act?

Not in this Congress, on present evidence. Two identical bills are pending: S. 907, introduced on 6 March 2025 by Senator Thom Tillis with Senator Richard Blumenthal, and H.R. 4145, introduced in the House by Representative Greg Murphy with a substantial bipartisan cosponsor list. Both were referred to the Judiciary Committees and have not moved.

The bills make three operative changes, each of which maps directly onto a problem described above:

Provision	Current law	What S. 907 / H.R. 4145 would do
Venue	Exclusive jurisdiction and venue in the Eastern District of North Carolina	Permit any district court within the Fourth Circuit to hear a CLJA action
Jury trial	No jury right, per the February 2024 district ruling	Restore an express right to a trial by jury
Causation	"At least as likely as not," construed by the district more demandingly than plaintiffs sought	State expressly that a claimant need show general causation

Camp Lejeune claimants held a third mass rally on Capitol Hill in September 2026, across two days, pressing for exactly these changes. Roll Call reported on 22 September that the bills remain stalled in both chambers with no realistic prospect of action until the chambers return after the midterm elections — by which time, as that reporting notes, the outline of a mass settlement may already be before the court in North Carolina.

That sequencing is the whole story of the legislative effort. A venue fix matters if thousands of cases must be tried; it matters much less if a framework resolves them administratively. A jury-trial fix matters if trials are the pricing mechanism; it matters much less if a Settlement Matrix is. The reform bills are, in effect, a hedge against the 30 October framework failing, and they are moving more slowly than the thing they hedge against.

Why this is not an MDL, and why the November results will not bind anyone

Coverage routinely calls the November cases "bellwethers" and the docket an "MDL." Neither is accurate, and the imprecision leads claimants to the wrong expectations.

This is not a Multidistrict Litigation (MDL). The Judicial Panel on Multidistrict Litigation (JPML) never centralized anything, because Section 804 sent every case to one district by statute. There is no transferee court, no Section 1407 remand at the conclusion of pretrial proceedings, and no Common Benefit Fund assessment of the kind the JPML process generates. The four judges are managing a single-district inventory using tools borrowed from MDL practice — a Plaintiff Fact Sheet-style intake, staged discovery, trial tracks, settlement masters — without the statutory scaffolding.

Nor is a Track 1 judgment binding on anyone else. A bench judgment in Mousser binds the parties to Mousser. It has no preclusive effect against a different claimant with kidney cancer, and no preclusive effect for the government against a claimant who was not a party. What it produces is information: a judicial finding, in writing, on the contested epidemiology, and a number. In a litigation where the parties are negotiating a matrix, information about how a judge values a kidney cancer death is worth more than a jury verdict would be in a system with no punitive damages and mandatory offsets, because it is transferable to a grid.

The distinction cuts against claimants in one respect worth stating plainly. In an MDL, a string of plaintiff bellwether wins creates leverage because the defendant faces thousands of individual trials it cannot staff. Here, the defendant is the United States, the trials are two or three days each before judges who already know the record, and there is no punitive exposure. Trial-capacity pressure, the ordinary engine of mass settlement, is weaker against this defendant than against a corporate one.

What it means for claimants' counsel, the government and the mass tort bar

For claimants' counsel. The Track 1 waiver has to be a documented conversation, not a procedural footnote. A client with multiple qualifying conditions who is offered a trial slot is being asked to trade claims for position, and the firm advancing them is advancing them on behalf of an inventory that benefits from the data point. That is a structural conflict familiar from Mass Tort leadership practice, and it is sharper here because no court-approved Common Benefit Fund compensates the individual whose claims are pruned. Firms should also be modeling offsets now rather than after a framework lands: for a long-service veteran with a high VA rating, the offset analysis can invert the ranking between an administrative offer and a litigated recovery.

For the government. The Justice Department has been resolving claims faster than it has been trying them, and the published figures show why: roughly $801 million paid by mid-July 2026 without a single judgment entered. The 30 October framework target is the point at which that strategy either scales into a global resolution or stops being sufficient. The emergency motion over the 27 September offer expiry, and the exposure-band dispute underlying it, are signals that the administrative program's credibility is now itself a litigation issue.

For the mass tort bar generally. Camp Lejeune is the working model for what a congressionally created cause of action against the United States looks like when it produces a six-figure claimant population. Every feature that distinguishes it from a conventional Mass Tort — single-district venue, no punitive damages, statutory offsets, no jury, an administrative pricing grid running in parallel with litigation — is a feature Congress could replicate in the next statutory compensation scheme. Firms building intake capacity around future federal exposure statutes should be reading the Camp Lejeune Track 1 trial structure as a template rather than an anomaly.

For funders. Third-Party Litigation Funding economics in this litigation are unusual and mostly unattractive. There is no punitive upside, recoveries are reduced by statutory offsets that are hard to model per claimant, the Statute of Limitations has closed so the book cannot grow, and the dominant resolution path is an administrative grid that prices claims below litigated expectations but pays in months rather than years. The asymmetry that makes mass tort funding work — a long tail with occasional very large outcomes — is largely engineered out of this one.

Frequently asked questions

What is a Camp Lejeune Track 1 trial?

It is one of the first single-plaintiff bench trials in the Camp Lejeune Justice Act litigation in the Eastern District of North Carolina, drawn from 25 Trial Plaintiffs selected in July 2024 across five designated diseases, with the first set for 9 November 2026.

Which diseases are in Camp Lejeune Track 1?

Kidney cancer, bladder cancer, leukemia, non-Hodgkin lymphoma and Parkinson's disease. The government argued for a narrower Track 1 of three diseases; the five-disease scope prevailed.

Do Camp Lejeune trial plaintiffs give up claims for other illnesses?

Yes. Each Track 1 Trial Plaintiff waived any claim that a condition outside Track 1 was caused by the water at Camp Lejeune, and had to amend the Short Form Complaint within ten days to remove the waived conditions.

Why is there no jury in Camp Lejeune trials?

Four judges of the Eastern District of North Carolina held in February 2024 that Congress did not clearly waive sovereign immunity as to jury trials in the Camp Lejeune Justice Act, so the cases are tried to the bench. The court declined to certify that ruling for interlocutory appeal in May 2024.

Does a Camp Lejeune court award reduce VA benefits?

No. The Department of Veterans Affairs states that a Camp Lejeune Justice Act award does not reduce VA disability payments or affect eligibility for VA health care. The reduction runs in the other direction: the court must offset the litigation award by disability awards, payments or benefits already received for the same exposure.

What happens if the parties miss the 30 October 2026 settlement deadline?

Nothing expires. The date is a court-set target for producing a global framework, not a statutory bar, and the court has indicated that failure would prompt consequences aimed at counsel rather than at claimants. The first trial would then proceed on 9 November 2026 as scheduled.